Novartis CEO Narasimhan Is Encouraged On US Drug Pricing Ahead Of Trump's Announcement
Executive Summary
New CEO offers his perspective on potential US drug pricing policy changes, including changes to Medicare Part B and pricing transparency. Pharma must also think more about social responsibility, he says, wading into a topic that will certainly be an issue for the new generation of industry leaders.
You may also be interested in...
Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows
A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing.
Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows
A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing.
Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies
No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.